Skip to main content

Vertex Pharmaceuticals operating cash flow

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

Vertex Pharmaceuticals's operating cash flow was $3.63 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was $643 million, down 48.2% from a year earlier.

Over the four quarters to 30 Sep 2026, operating cash flow was $3.69 billion.

From Vertex Pharmaceuticals's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 3 Nov 2026.

Fiscal 2025
$3.63B
Q3 FY2026
$643M
−48.2% on a year
Growth over 9 years
+35.5%
a year, FY 2016–FY 2025

Operating cash flow by fiscal year

$236MFY 2016$845MFY 2017+258%$1.27BFY 2018+50.3%$1.57BFY 2019+23.5%$3.25BFY 2020+107%$2.64BFY 2021−18.7%$4.13BFY 2022+56.2%$3.54BFY 2023−14.3%−$493MFY 2024$3.63BFY 2025

Change on the year before, under each year. From FY 2016 to FY 2025, Vertex Pharmaceuticals's operating cash flow went from $236 million to $3.63 billion, a compound annual change of +35.5%; the highest was $4.13 billion in FY 2022.

Vertex Pharmaceuticals operating cash flow, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$236M$845M$1.27B$1.57B$3.25B$2.64B$4.13B$3.54B−$493M$3.63B
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Operating cash flow by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Vertex Pharmaceuticals operating cash flow, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Operating cash flow$585M$819M$1.07B$1.24B$498M$1.43B$1.13B$643M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How operating cash flow is measured

Operating cash flow is the cash generated by the company's operations in the period, as reported on its cash flow statement. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Vertex Pharmaceuticals's other figures

Operating cash flow of comparable companies

Everything on VRTX, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.